/images/ppid_59c68470-image-176785259768882144.webp)
/images/ppid_59c68470-image-176785009534884752.webp)
/images/ppid_a911dc6a-image-176785006075097440.webp)
What is the story about?
Shares of Panacea Biotec gained 7% after the company announced the completion of enrolment in its Phase III clinical trial for its dengue vaccine candidate, DengiAll.
In a regulatory update, the company said a total of 10,335 participants have been enrolled in the late stage trial. Each participant will be monitored for a period of two years after receiving either the vaccine or a placebo to assess the efficacy and immunogenicity of the candidate.
DengiAll is a tetravalent dengue vaccine being developed in India and is designed as a single shot formulation.
The vaccine uses live, weakened strains of all four dengue virus serotypes DEN1, DEN2, DEN3 and DEN4 in a single dose. Panacea Biotec said DengiAll is expected to be the country’s first indigenous single dose dengue vaccine, with a potential market launch targeted by 2027.
The company has been working on the vaccine since 2008, underscoring the long and complex development timeline typically associated with dengue vaccines.
Experts said that dengue vaccine development has historically been challenging. Sanofi had withdrawn its dengue vaccine Dengvaxia from the Philippines following safety concerns and later discontinued its manufacture in 2025 due to low demand.
Studies had shown that Dengvaxia increased the risk of severe dengue in individuals who had not been previously infected.
Other global efforts are also underway. Japanese drugmaker Takeda introduced its dengue vaccine Qdenga in 2022, while the Butantan Institute in Brazil has developed the Butantan DV vaccine, which is yet to enter commercial production.
Health authorities continue to stress that preventing mosquito bites remains the primary line of defence against dengue, even as vaccine research progresses.
In a regulatory update, the company said a total of 10,335 participants have been enrolled in the late stage trial. Each participant will be monitored for a period of two years after receiving either the vaccine or a placebo to assess the efficacy and immunogenicity of the candidate.
DengiAll is a tetravalent dengue vaccine being developed in India and is designed as a single shot formulation.
The vaccine uses live, weakened strains of all four dengue virus serotypes DEN1, DEN2, DEN3 and DEN4 in a single dose. Panacea Biotec said DengiAll is expected to be the country’s first indigenous single dose dengue vaccine, with a potential market launch targeted by 2027.
The company has been working on the vaccine since 2008, underscoring the long and complex development timeline typically associated with dengue vaccines.
Experts said that dengue vaccine development has historically been challenging. Sanofi had withdrawn its dengue vaccine Dengvaxia from the Philippines following safety concerns and later discontinued its manufacture in 2025 due to low demand.
Studies had shown that Dengvaxia increased the risk of severe dengue in individuals who had not been previously infected.
Other global efforts are also underway. Japanese drugmaker Takeda introduced its dengue vaccine Qdenga in 2022, while the Butantan Institute in Brazil has developed the Butantan DV vaccine, which is yet to enter commercial production.
Health authorities continue to stress that preventing mosquito bites remains the primary line of defence against dengue, even as vaccine research progresses.
